… single agents and in combination with chemotherapy, antiangiogenic agents, and ionizing
… inhibitors have no effect on tumor cells with the complete absence of the PARP1 enzyme. …

… ovarian cancer is surgery combined with chemotherapy. In … , PARP inhibitors can capture
PARP1, resulting in DNA damage … to the clinical trials of PARP inhibitors on ovarian cancer, …

… -based chemotherapy [63]. Clinical trials of niraparib in ovarian cancer mainly concentrated
… DNA damage occurs following chemotherapy, resulting in PARP1 protein activation that …

… and the results from the clinical studies that investigated the effects … Among all kinds of PARP,
PARP-1 is the most important … over chemotherapy when used in relapsed ovarian cancers. …

… human ovarian cancer cells transfected with PARP-1 small … of cytotoxic chemotherapy (51).
Promising data from more recent … III clinical trials testing veliparib not only in ovarian cancer, …

… inhibitorchemotherapy hybrid targeting HR deficient cancers … single arm phase II trial,
monotherapeutic effect of Rucaparib … breast cancer where patients had received PARP-1 inhibitor …

… Pathways of resistance to PARPi and chemotherapy have been … due to exclusion from clinical
trials. Bevacizumab concurrently … PARP1 function can be affected due to mutations or post-…

… chemotherapy and as palliative treatment of platinum-resistant disease. Germline BRCA testing
should be offered to all patients with ovarian cancer… to readily detect PARP1–and PARP2…

… evaluated in late-stage clinical trials of ovarian cancer (OC). … pathway components and role
of PARP1 for each pathway. (… with chemotherapeutic agents in early phase I clinical trials, …

… is cytoreductive surgery followed by cytotoxic chemotherapy. … -blind, phase Ⅲ clinical trial
that assessed the efficacy of … In ovarian cancer cell lines, PARP1 expression is positively …